Our mission is to become a worldwide reference for education in the field for all professionals involved in the process to disseminate knowledge & skills of Acute Cardiovascular Care.
Our mission is to promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging in Europe.
Our mission is to promote excellence in research, practice, education and policy in cardiovascular health, primary and secondary prevention.
Our mission is to reduce the burden of cardiovascular disease in Europe through percutaneous cardiovascular interventions.
Our mission is to improve the quality of life of the population by reducing the impact of cardiac rhythm disturbances and reduce sudden cardiac death.
Our mission is to improve quality of life and longevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.
The ESC Working Groups' goal is to stimulate and disseminate scientific knowledge in different fields of cardiology.
The ESC Councils' goal is to share knowledge among medical professionals practising in specific cardiology domains.
OUR MISSION: TO REDUCE THE BURDEN OF CARDIOVASCULAR DISEASE
Dr. Stine Darkner
Prof. Karl-Heinz Kuck,
By Stine Darkner, (Copenhagen, Denmark)View Discussant report
Read the press releaseOpen the PresentationWatch the Webcast
List of Authors: Stine Darkner, MD, Xu Chen, MD, DMSci, Jim Hansen, MD, DMSci, Steen Pehrson, MD, DMSci, Arne Johannessen, MD, DMSci, Jonas B Nielsen, MD, Jesper Hastrup Svendsen, MD, DMSci
PURPOSEPatients undergoing catheter ablation for atrial fibrillation (AF) often experience recurrent arrhythmias within the first few months post ablation. We aimed to investigate whether short term use of amiodarone to prevent early arrhythmias following radiofrequency ablation for AF could reduce later recurrence.METHODS In a 2-centre, randomized, double blind, placebo-controlled study, we randomized a total of 212 patients undergoing AF ablation. Patients were stratified according to type of AF (paroxysmal/persistent) and history of previous AF ablation and randomly assigned to 8 weeks of oral amiodarone therapy or matched placebo following catheter ablation. Patients were followed for 6 months. Analyses were performed according to the intention-to-treat principle. RESULTSOf 212 enrolled patients (median age 61 [IQR 54-66], 83% male, 50% paroxysmal, 29% with history of previous ablation), 206 patients were available for analysis of the primary endpoint which was any documented atrial tachyarrhythmia lasting >30 seconds following a blanking period of 3 months. This was observed in 42/107 (39%) in the amiodarone group versus 48/99 (48%) in the placebo group (p=0.18). Among the secondary endpoints, the amiodarone group showed significantly lower rate of atrial tachyarrhythmia related hospitalizations (rate ratio=0.43; 95% CI=0.23-0.77, P=0.006) and cardioversions (rate ratio 0.36; 95% CI 0.20-0.62, p=0.0004) within the blanking period.CONCLUSIONShort term oral amiodarone treatment following ablation for paroxysmal or persistent AF did not significantly reduce recurrence of atrial tachyarrhythmias at 6 months follow-up, but it more than halved atrial arrhythmia related hospitalization and cardioversion rates during the blanking period.
By Karl-Heinz Kuck, FESC (Hamburg, Germany)See Presenter abstract
Open the presentationWatch the Webcast
Hot Line: Coronary artery disease and atrial fibrillation
© 2017 European Society of Cardiology. All rights reserved